New lengths of Cordis' biliary stent
This article was originally published in Clinica
Executive Summary
Cordis has received 510(k) marketing clearance from the US FDA for new lengths of its S.M.A.R.T. Nitinol transhepatic biliary stent. The approval covers lengths of 120 and 150mm. These stents are designed for the palliative treatment of malignant strictures in the biliary tree that can restrict the flow of digestive fluids and compromise digestion. Cordis, a subsidiary of Johnson & Johnson, said that the S.M.A.R.T. devices may decrease the need for additional stents to cover the full narrowing of the bile duct.